Recent Updates
Recently added Catalysts

Apnimed, Inc.

APMDFDA catalysts, PDUFA dates & pipeline intelligence
$16.28
▼ -0.64 · -3.78%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full APMD financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
256.89 K
Value Traded
4.23 M
Short % Float
5.08%
Days to Cover
4.5
+2.97%Week
-1.9%1 Month
-49.98%3 Month

Cash Data

Unlock APMD cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
677.75 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
364.98 M
Total Shares
41.63 M
Float Shares
31.25 M
Insiders
24.95%
Institutions
49.86%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA Date
AD109
mild, moderate and severe obstructive sleep apnea
PDUFASmall MoleculesRespiratory
Unlock every APMD catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

APMD Catalyst Timeline

Dated clinical, regulatory and corporate events for Apnimed, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Apnimed, Inc.

42Total events
5Upcoming
8Tier-1 (high impact)
2025 to 2027Coverage

Upcoming catalysts 2

T1PDUFA Date
Subscribe to view catalyst details
AD109Filed
T2Timing Guidance
Subscribe to view catalyst details
AD109Filed

Event history 22

●Grant / FundingCorporate
Inducement grants of stock options to 19 new non-executive employees
●R&D DayPresentation
Apnimed fireside chat at Cantor Global Healthcare Conference 2026
▲FDA Filing AcceptedAD109FiledRegulatory Filing
FDA accepted NDA for AD109 (Oxnimbi) for OSA
obstructive sleep apneasource ↗
●Management ChangeCorporate
Appointed Kevin Lind as CEO, Michael Kelly as CFO, and Steven Spector as Chief Legal Officer
●Quarterly UpdateCorporate
Reported second quarter 2026 financial results
●Debt Royalty FinancingCorporate
Completed senior secured credit facility for up to $150 million
▲Partnership / LicenseCorporate
Strategic monetization of interest in Shionogi-Apnimed Sleep Science
●PublicationAD109FiledPresentation
Published Phase 3 SynAIRgy results in American Journal of Respiratory and Critical Care Medicine
obstructive sleep apneasource ↗
▲FDA Filing AcceptedAD109FiledRegulatory Filing
FDA accepted NDA for AD109 (Oxnimbi) for adults with OSA
obstructive sleep apneasource ↗
●Equity OfferingCorporate
Completed upsized initial public offering for gross proceeds of $220.8 million
Unlock the full APMD catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How APMD actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-21AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg) Phase 3 data presentation Phase 3
Unlock all APMD historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
5
Drugs Scored
rNPV / MCap
Top Drug
Top 37%
Micro Cap
(rank 269 of 725)
Percentile Rank
Showing 7 of 14 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Aroxybutynin and Atomoxetine Small MoleculesNCT06566820OSAPhase 3 ENROLLING BY_INVITATION 1,280Jun 30, 2026
AD109 Small MoleculesCompletedNCT06400615OSAPhase 3 COMPLETED 1,346Dec 26, 2024
AD109 Small MoleculesCompletedNCT04580394Obstructive Sleep ApneaNDA/BLA COMPLETED 60May 28, 2021
AD109 Small MoleculesCompletedNCT05071612OSA - Obstructive Sleep ApneaNDA/BLA COMPLETED 294Aug 3, 2022
AD113 Small MoleculesCompletedNCT04905979Obstructive Sleep ApneaPhase 2 COMPLETED 21May 31, 2023
Dosing 1: Atomoxetine Small MoleculesCompletedNCT05101122Obstructive Sleep ApneaPhase 1/2 COMPLETED 15Apr 18, 2022
Period A Small MoleculesCompletedNCT05793684OSAPhase 2 COMPLETED 25Nov 9, 2023
Unlock the APMD pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every APMD program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every APMD trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock APMD insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
SEKHRI PAUL JDirectorBuyOffering 12,500 12,500 held$16.00 08/03/2026
Unlock the full APMD insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in APMD for Q2 2026.
Unlock every fund holding APMD
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in APMD
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see APMD ownership
Insider and institutional ownership, quarter by quarter.

APMD Short Interest

Shares sold short, counted twice a month.

5.08%
Short % of Float
of tradable shares sold short
1.6M
Shares Sold Short
-12.0% vs prior count
4.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
349.3K
Avg Daily Volume
the average used for days to cover
Unlock APMD short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock APMD option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live APMD option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock APMD options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How APMD ranks across every disease it competes in

Competitive Position is a premium feature
See how APMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

APMD News

-APMD
Nov 16, 2026
APMDFDA Updates
▼ -3.8%today

Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Apnimed reported a $29.5 million net loss for the third quarter of 2026. The company holds $351.8 million in cash to fund operations and a potential U.S. launch of Oxnimbi. The NDA for AD109 remains under FDA review with a PDUFA date of February 28, 2027. Apnimed also presented five abstracts on AD109 data at the CHEST 2026 meeting.

Read more →
-APMD
Nov 5, 2026
APMDGeneral
▲ +6.6%on this news· ran to +19% by day 3

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apnimed, Inc. announced the grant of 331,000 stock options to 14 new non-executive employees under its 2026 Inducement Plan. The options have an exercise price of $15.40, matching the closing price on the grant date. This initiative aims to enhance recruitment and retention as the company advances its oral therapy candidate, AD109, for obstructive sleep apnea (OSA).

Read more →
-APMD
Oct 12, 2026
APMDConferences/Events

Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026

Apnimed, Inc. announced that five abstracts have been accepted for presentation at CHEST 2026, including two late-breaking abstracts on their investigational drug AD109 for obstructive sleep apnea. The meeting will feature discussions on the Phase 3 trials and the potential impact of AD109 on OSA management. The FDA is currently reviewing Apnimed's NDA for AD109, with a PDUFA goal date set for February 28, 2027.

Read more →
-APMD
Sep 8, 2026
APMDFDA Updates

Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Apnimed, Inc. reported its second quarter 2026 financial results, highlighting the FDA's acceptance of its NDA for AD109, proposed as Oxnimbi, with a PDUFA date set for February 28, 2027. The company successfully completed an IPO, raising $220.8 million, and strengthened its leadership team. Oxnimbi aims to be the first oral treatment for obstructive sleep apnea, addressing a significant unmet need in the market.

Read more →
-APMD
Aug 3, 2026
APMDGeneral

Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Apnimed, Inc. has successfully closed its upsized initial public offering, raising $220.8 million through the sale of 13.8 million shares. The offering included the full exercise of underwriters' option to purchase additional shares. Apnimed's common stock began trading on the Nasdaq Global Select Market on July 31, 2026. The company is focused on developing novel therapies for sleep-related breathing diseases, particularly obstructive sleep apnea.

Read more →
-APMD
Jul 31, 2026
APMDGeneral

Apnimed Announces Pricing of Upsized Initial Public Offering

Apnimed, a late-stage clinical pharmaceutical company, has announced the pricing of its upsized initial public offering (IPO) of 12 million shares at $16.00 each. The IPO is expected to raise approximately $192 million, with shares set to begin trading on the Nasdaq Global Select Market on July 31, 2026. The offering includes a 30-day option for underwriters to purchase additional shares.

Read more →
-APMD
Jul 14, 2026
APMDFDA Updates

Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea

Apnimed announced the FDA's acceptance of its New Drug Application for AD109, an investigational oral pill aimed at treating adults with obstructive sleep apnea (OSA). The FDA has set a target action date of February 28, 2027. If approved, AD109 could be the first oral pharmacologic therapy addressing the neuromuscular causes of OSA. The NDA is backed by positive results from Phase 3 clinical trials.

Read more →
-APMD
Jul 1, 2026
APMDGeneral

Apnimed Strengthens Leadership Team with Appointments of Industry Veterans Michael Kelly as Chief Financial Officer and Steven Spector as Chief Legal Officer and Head of Corporate Affairs

Apnimed has appointed Michael Kelly as Chief Financial Officer and Steven Spector as Chief Legal Officer and Head of Corporate Affairs. This leadership transition follows the recent appointment of Kevin Lind as CEO and is part of a strategy to prepare the company for growth. Both Kelly and Spector bring significant experience in finance and legal compliance, respectively, as Apnimed advances towards the potential commercialization of its investigational drug AD109 for obstructive sleep apnea.

Read more →
-APMD
Jun 10, 2026
APMDConferences/Events

Apnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea

Apnimed, Inc. announced that six abstracts, including an oral presentation, will be featured at SLEEP 2026, focusing on pooled Phase 3 data for AD109, its lead candidate for obstructive sleep apnea. The presentations underscore the urgent need for improved awareness and education regarding OSA, highlighting the challenges faced by patients in receiving timely treatment. AD109 aims to simplify intervention and improve patient outcomes in this chronic condition.

Read more →
-APMD
Jun 8, 2026
APMDGeneral

Apnimed Appoints Experienced Pharmaceutical Executive Kevin R. Lind as Chief Executive Officer to Implement Next Phase of Growth Strategy

Apnimed has appointed Kevin R. Lind as the new Chief Executive Officer, succeeding founder Lawrence G. Miller, MD, who will take on the role of Vice Chair of the Board. Mr. Lind brings extensive experience in the pharmaceutical industry, including leadership roles that have resulted in successful acquisitions. This leadership change is aimed at implementing the next phase of the company's growth strategy.

Read more →
-APMD
May 18, 2026
APMDPhases

Apnimed Announces Publication of its Phase 3 SynAIRgy Trial of AD109 for Obstructive Sleep Apnea in the American Journal of Respiratory and Critical Care Medicine

Apnimed announced the publication of its Phase 3 SynAIRgy trial results for AD109, an investigational oral treatment for obstructive sleep apnea (OSA). The study demonstrated significant improvements in oxygenation and reductions in apnea-hypopnea index, supporting AD109's potential as a first-in-class therapy. A New Drug Application has been submitted to the FDA, with a target action date expected in early 2027.

Read more →
-APMD
May 11, 2026
APMDConferences/Events

Apnimed Announces Three Oral Presentations and a Late-breaking Poster at the American Thoracic Society (ATS) 2026 International Conference

Apnimed, Inc. announced multiple presentations at the ATS 2026 International Conference, including three oral presentations and a late-breaking poster. These will showcase findings from the Phase 3 trials of AD109, their lead product candidate for obstructive sleep apnea. The presentations aim to highlight the drug's efficacy in reducing snoring and cardiovascular risks associated with the condition.

Read more →

About Apnimed, Inc.

Cambridge, MA apnimed.com
Headquarters39 JOHN F. KENNEDY STREET, 4TH FLR., CAMBRIDGE, MA, 02138
BIOPHARMAWATCH ELITE
Trade the next APMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime